Oruka Therapeutics (ORKA) Reports Strong Phase 2a Psoriasis Data Amid Mixed Market Signals
· gurufocus.com
On September 23, 2026, Oruka Therapeutics Inc (NASDAQ: ORKA) announced encouraging Week 28 results from its EVERLAST-A Phase 2a trial evaluating ORKA-001, an IL
On September 23, 2026, Oruka Therapeutics Inc (NASDAQ: ORKA) announced encouraging Week 28 results from its EVERLAST-A Phase 2a trial evaluating ORKA-001, an IL...